Invesco opens ₹1,000-minimum pharma and healthcare fund on August 18
What's the deal? Invesco Mutual FundDealroom has a profile for this one. Try Dealroom → has launched the Invesco India Pharma and Healthcare FundDealroom has a profile for this one. Try Dealroom →, an open-ended equity scheme investing in pharmaceutical, healthcare, and allied companies. The new fund offer opens on August 18 and closes on September 1. Aditya Khemani, head of equity and fund manager at Invesco, will run it.
What's the endgame? The scheme spans the whole healthcare ecosystem, not just drugmakers. Its portfolio can hold hospitals, diagnostic firms, contract development and manufacturing organisations (CDMOs), contract research organisations (CROs), medical device makers, insurers, and other allied businesses.
The strategy: Invesco said it will target businesses with sustainable competitive advantages and clear growth visibility across the healthcare value chain. The fund is benchmarked against the BSE Healthcare TRI.
Why now? The fund house cited long-term drivers: rising healthcare spending, wider insurance coverage, ageing demographics, more lifestyle-related diseases, and expanding infrastructure. It also flagged India's role in global pharmaceutical manufacturing and outsourcing.
The terms: The minimum lump-sum investment is ₹1,000, with the minimum SIP at ₹100. An exit load of 0.50% applies to redemptions within three months of allotment; none thereafter.
What could go wrong? A sector fund is more exposed to the valuation cycles of its underlying sector than a diversified scheme. That ties returns closely to developments in healthcare and related businesses.
The signal: The launch adds to a growing crop of sector- and theme-focused equity schemes competing for Indian investors betting on concentrated bets over broad diversification.
Read more: CNBC-TV18
Image credit: Monash Public Library Service
